Q-omics provides the consensus-scored TRDMT1 profile across patient tissues and cancer cell-line models. TRDMT1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRDMT1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TRDMT1 RNA expression shows 21,262 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TRDMT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRDMT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRDMT1 survival associations across molecular data types. TRDMT1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRDMT1 RNA expression–survival associations across cancer types. High TRDMT1 expression shows unfavorable associations in KICH and BLCA, but favorable associations in KIRC, LUAD, UCS and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRDMT1 RNA expression.
This table summarizes TRDMT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRDMT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRDMT1 shows lower tumor expression in THCA, KICH, LUAD, BRCA and LUSC and higher tumor expression in CHOL. The THCA box plot shows higher TRDMT1 RNA expression in normal versus tumor tissue (log2 FC = −0.762, t-test p < 0.001).
This table shows molecular features associated with TRDMT1 in patient tissues and cancer cell lines. In patient samples, TRDMT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRDMT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
